Tezspire Use In Pregnancy & Lactation

Pregnancy: There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of tezepelumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Human IgG antibodies, such as tezepelumab, are transported across the placenta barrier; therefore, Tezspire may be transmitted from the mother to the developing foetus.
As a precautionary measure, it is preferable to avoid the use of Tezspire during pregnancy unless the expected benefit to the pregnant mother is greater than any possible risk to the foetus.
Breast-feeding: It is unknown whether tezepelumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; consequently, a risk to the breast-fed child cannot be excluded during this short period.
For this specific period, a decision should be made whether to discontinue/abstain from tezepelumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of therapy to the woman.
Afterwards, tezepelumab could be used during breast-feeding if clinically needed.
See Pharmacology: Toxicology: Preclinical safety data under Actions for information on the excretion of tezepelumab in animal (cynomolgus monkey) milk.
Fertility: There are no fertility data in humans. Animal studies showed no adverse effects of tezepelumab treatment on fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).